Searchable abstracts of presentations at key conferences in endocrinology

ea0090oc7.5 | Oral Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023

A novel filamin A-binding molecule may significantly enhance SST2 antitumoral actions in GH-secreting PitNET cells

Marra Giusy , Treppiedi Donatella , Muro Genesio Di , Mangili Federica , Catalano Rosa , Esposito Emanuela , Nozza Emma , Locatelli Marco , Lania Andrea , Sala Elisa , Ferrante Emanuele , Arosio Maura , H. Burns Lindsay , Mantovani Giovanna , Peverelli Erika

The main target of pharmacological therapy for growth hormone (GH)-secreting pituitary tumors (GH-PitNET) is the somatostatin receptor type 2 (SST2). However, approximately half of patients treated with octreotide, an SST2 agonist, show a low response rate or are octreotide-resistant. Here we present mechanistic data that shows co-treatment with simufilam, a novel oral therapeutic candidate, enhances sensitivity to octreotide. We previously showed that the cytoskeleton protein...